In terms of actionable targets, common druggable mutations for CRC, including proto-oncogene B-Raf (BRAF) mutations and receptor tyrosine-protein erbB-2 kinase (ERBB2) amplification, could be detected using this commercial cfDNA assay. Here, BRAF is linked to colorectal carcinoma.